Follow The Filings

CRVS Corvus Pharmaceuticals

Corvus Pharmaceuticals earnings company data as of 4:00 PM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS -0.21 — —
Rev — — —

Insider trades

Open-market buys and sales by CRVS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRVS insider trades
  • $334K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. David Scott Moore Director
    Buy
    $250K 21,700 shares at $11.53 New stake
    Traded Jun 11 Filed Jun 15
    ↗
  2. Richard A Miller MD CEO
    Buy
    $83K 6,932 shares at $12.04 +0.6% to stake
    Traded May 18 Filed May 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf